Dlbcl Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
S
Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
2022-04-06
Apr 6, 2022
A
Recruiting
  • Advanced Solid Tumor
  • +9 more
  • Phoenix, Arizona
  • +20 more
2022-03-31
Mar 31, 2022
M
Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2022-03-30
Mar 30, 2022
I
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
M
Recruiting
  • DLBCL
  • Diffuse Large B-Cell Lymphoma
  • Zilovertamab vedotin
  • +4 more
  • Whittier, California
  • +4 more
2022-03-23
Mar 23, 2022
T
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
F
Recruiting
  • DLBCL
  • Alessandria, Italy
  • +41 more
2022-03-21
Mar 21, 2022
H
Recruiting
  • CLL/SLL
  • +8 more
  • Atlanta, Georgia
  • +3 more
2022-02-24
Feb 24, 2022
B
Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
2022-03-08
Mar 8, 2022
C
Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
2022-03-07
Mar 7, 2022
K
Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Louisville, Kentucky
    Norton Cancer Institute
2022-03-01
Mar 1, 2022
S
Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2022-02-15
Feb 15, 2022
A
Enrolling by invitation
  • Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
  • +4 more
  • AUTO CAR T cell therapy
  • London, United Kingdom
  • +3 more
2022-02-02
Feb 2, 2022
S
S
Recruiting
  • B-ALL
  • +3 more
  • Stanford, California
    Stanford Medical Center
2022-01-14
Jan 14, 2022
U
Recruiting
  • DLBCL
  • Lymphoma, B-Cell
  • Polatuzumab vedotin
  • +4 more
  • Rochester, New York
    University of Rochester
2022-01-06
Jan 6, 2022
A
Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
2021-11-19
Nov 19, 2021
U
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2021-11-01
Nov 1, 2021
M
Terminated
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
2021-09-29
Sep 29, 2021
U
Recruiting
  • DLBCL
  • Rituximab Prednisone
  • +4 more
  • Rochester, New York
    University of Rochester
2021-09-08
Sep 8, 2021
I
Not yet recruiting
  • DLBCL
  • Shanghai, Shanghai, China
    Ruijin Hospital affiliated to Shanghai Jiao Tong University Scho
2021-09-01
Sep 1, 2021